| P2093 | author name string | Fang Li | |
| | Hao Liu | |
| | Fan Wang | |
| | Zhaofei Liu | |
| | Di Fan | |
| | Bing Jia | |
| | Huiyun Zhao | |
| | Jiyun Shi | |
| | Chengyan Dong | |
| | Xiaona Jin | |
| P2860 | cites work | Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. | Q44203808 |
| | Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers | Q46083932 |
| | microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide | Q46115376 |
| | Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors | Q46562630 |
| | Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival | Q46619794 |
| | 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. | Q53166290 |
| | Differential diagnosis of solitary pulmonary nodules using ⁹⁹mTc-3P₄-RGD₂ scintigraphy. | Q53205623 |
| | Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature | Q83033194 |
| | Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy | Q83236149 |
| | Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers | Q84219938 |
| | Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2 | Q85199533 |
| | Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent | Q33867187 |
| | Integrin alpha(v)beta(3)-Targeted Cancer Therapy | Q33983773 |
| | Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models | Q34230220 |
| | Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme | Q34880953 |
| | Integrin targeted delivery of radiotherapeutics | Q34912696 |
| | Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability | Q35167459 |
| | The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines | Q36218369 |
| | Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers | Q37060623 |
| | Targeted radionuclide therapy | Q37148148 |
| | Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers | Q37178786 |
| | Imaging of integrin alphavbeta3 expression | Q37181773 |
| | Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial | Q37302618 |
| | Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors | Q37649127 |
| | Strategies to improve radiotherapy with targeted drugs | Q37856721 |
| | Radiolabelled RGD peptides for imaging and therapy | Q37990409 |
| | A novel treatment for glioblastoma: integrin inhibition | Q37997092 |
| | RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis | Q38042484 |
| | Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin | Q39181085 |
| | Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model | Q39458986 |
| | Radiolabeled peptides: valuable tools for the detection and treatment of cancer | Q39596344 |
| | Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy | Q39920498 |
| | alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. | Q39979513 |
| | (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression | Q40118679 |
| | Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. | Q40365959 |
| | Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. | Q40587263 |
| | 90Y/177Lu-DOTATATE therapy: survival of the fittest? | Q42906685 |
| | Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer. | Q43235160 |
| | Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. | Q43824477 |
| P433 | issue | 3 | |
| P921 | main subject | lutetium-177 | Q18882670 |
| P304 | page(s) | 256-266 | |
| P577 | publication date | 2014-01-18 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar | |
| P478 | volume | 4 | |